ProStrakan Group Plc
(Public, LON:PSK) Watch this stockFind more results forLON: PSK
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | -26.22% | -40.46% |
| Operating margin | -18.11% | -37.61% |
| EBITD margin | - | -32.62% |
| Return on average assets | -20.71% | -24.02% |
| Return on average equity | -509.13% | -102.31% |
| Employees | 238 | - |
Address
Galabank Business Park
Galashiels, ENG TD1 1QH
United Kingdom - Map
+44-1896-664000 (Phone)
+44-1896-664001 (Fax)
Galashiels, ENG TD1 1QH
United Kingdom - Map
+44-1896-664000 (Phone)
+44-1896-664001 (Fax)
Website links
Company website:
http://www.prostrakan.com/
http://www.prostrakan.com/
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
ProStrakan Group Plc discussions
View all discussions »Description
ProStrakan Group plc is an international specialty pharmaceutical company. The Company is engaged in the development and commercialization of prescription medicines for the treatment of therapeutic needs in global markets. The Company markets its range of products through its commercial operation based primarily in the United Kingdom, United States of America, Germany, France, Spain and Sweden. The Company’s products include Sancuso, Abstral/Rapinyl, Rectogesic/Cellegesic, Tostran/Fortigel and Adcal-D3.
Officers and directors
| J. Wilson W. Totten | Chief Executive Officer, Executive Director | |
| Allan Mark Watson | Chief Financial Officer, Director | |
| Mark Andrew Webster | Vice President - Global Strategic Marketing and Head of North America | |
| Andrew F. McLean | Company Secretary, General Counsel | |
| Nigel Atherton | Head - Global Development | |
| Abid Karim | Head - European Commercial Operations | |
| Tom Stratford | Head - Global Business Development | |
| Peter Vance Allen | Non-Executive Chairman of the Board | |
| Michael J. Asbury | Non-Executive Director | |
| Francis J.T. Fildes | Non-Executive Director |